PHARMACOECONOMIC ANALYSIS OF THERAPY REGIMENS FOR AGGRESSIVE 79 LYMPHOMA AND HODGKIN LYMPHOMA

Abstract

The registration of new drugs significantly expands the possibilities of hematologists and oncologists in the treatment of tumors of lymphoid tissue. The cost of new monoclonal antibodies, inhibitors of various signaling pathways and immune checkpoints disproportionately exceeds the direct cost of "classical" programs of combined cytostatic therapy. The regimens included in the National Clinical Guidelines remain the basis of first-line therapy, are combined with new agents, and are the standards of comparison of treatment efficacy for new agents. Regional population registries can be a source of useful information on the quantities of basic first- and subsequent-line cytostatic agents needed and the size of the financial costs of providing therapy to patients with hemoblastosis.